Evogene (EVGN) Competitors $1.37 -0.08 (-5.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.44 +0.06 (+4.74%) As of 07/11/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, TOMZ, ENFY, SDST, SNES, GURE, CNEY, NITO, BSLK, and HGASShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Stardust Power (SDST), Senestech (SNES), Gulf Resources (GURE), CN Energy Group. (CNEY), N2OFF (NITO), Bolt Projects (BSLK), and Global Gas (HGAS). Evogene vs. Its Competitors Carisma Therapeutics TOMI Environmental Solutions Enlightify Stardust Power Senestech Gulf Resources CN Energy Group. N2OFF Bolt Projects Global Gas Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends. Which has more risk & volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Do analysts rate CARM or EVGN? Carisma Therapeutics currently has a consensus target price of $1.93, suggesting a potential upside of 381.25%. Evogene has a consensus target price of $3.50, suggesting a potential upside of 155.47%. Given Carisma Therapeutics' higher probable upside, equities analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of CARM or EVGN? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.85-$60.48M-$1.56-0.26Evogene$8.51M0.86-$16.49M-$2.69-0.51 Is CARM or EVGN more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Evogene -224.82%-102.40%-39.19% Does the media prefer CARM or EVGN? In the previous week, Evogene had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 1 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 1.89 beat Evogene's score of 0.73 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Very Positive Evogene Positive SummaryCarisma Therapeutics beats Evogene on 9 of the 17 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.35M$2.94B$5.55B$9.09BDividend YieldN/A2.45%5.07%4.03%P/E Ratio-0.5110.0322.7821.11Price / Sales0.86292.01432.0899.75Price / CashN/A41.0526.2427.98Price / Book0.497.638.125.50Net Income-$16.49M-$55.05M$3.19B$250.38M7 Day Performance0.74%8.43%3.62%4.79%1 Month Performance-0.72%8.14%5.98%9.59%1 Year Performance-78.43%1.62%29.39%16.41% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.687 of 5 stars$1.37-5.5%$3.50+155.5%-78.4%$7.35M$8.51M-0.51140CARMCarisma Therapeutics3.2738 of 5 stars$0.40-2.0%$1.93+387.3%-66.7%$16.84M$19.63M-0.2520Positive NewsTOMZTOMI Environmental Solutions3.3586 of 5 stars$1.05-2.8%$3.50+233.3%+29.5%$21.62M$7.74M-6.1820Gap DownENFYEnlightifyN/A$1.10+1.3%N/AN/A$17.57M$95.85M-0.56424Earnings ReportGap UpHigh Trading VolumeSDSTStardust Power3.1678 of 5 stars$0.21+0.6%$5.11+2,357.9%N/A$12.44MN/A-0.28N/AHigh Trading VolumeSNESSenestech1.6864 of 5 stars$5.13-0.2%$10.00+94.9%-15.1%$11.55M$1.86M-0.6730Positive NewsGUREGulf Resources1.2695 of 5 stars$0.67-2.4%N/A-39.1%$9.21M$7.66M-0.12420Positive NewsCNEYCN Energy Group.0.5898 of 5 stars$2.65-1.9%N/A-80.1%$8.13M$50.96M0.00160NITON2OFF1.7045 of 5 stars$0.25+0.9%N/A-50.5%$6.53M$210K0.002News CoverageBSLKBolt ProjectsN/A$2.50-2.7%N/AN/A$5.30M$1.37M0.0012HGASGlobal GasN/A$0.10-28.2%N/A-34.9%$1.15MN/A0.002Gap Down Related Companies and Tools Related Companies CARM Competitors TOMZ Competitors ENFY Competitors SDST Competitors SNES Competitors GURE Competitors CNEY Competitors NITO Competitors BSLK Competitors HGAS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
